Table 2.
PP3M treatment patterns
| Patients adequately transitioning from PP1M to PP3M (N = 324) |
|
|---|---|
| Observation period, months, mean ± SD [median] | 11.1 ± 5.7 [11.5] |
| Patients with ≥ 6 months of observation period, n (%) | 248 (76.5) |
| Patients with ≥ 12 months of observation period, n (%) | 151 (46.6) |
| Duration of continuous PP3M therapya, days, mean ± SD [median] | 243.8 ± 162.3 [197.5] |
| Number of PP3M claims, mean ± SD [median] | 3.2 ± 2.0 [3.0] |
| Distribution of the number of PP3M claims, n (%) | |
| 1 | 77 (23.8) |
| 2 | 71 (21.9) |
| 3 | 51 (15.7) |
| 4 or more | 125 (38.6) |
| Dosing patterns | |
| First dose | |
| Patients with a first dose, n (%) | 324 (100.0) |
| Days since last PP1M dose, mean ± SD [median] | 26.6 ± 12.2 [28.0] |
| Dose strength (mg), n (%) | |
| 273 | 2 (0.6) |
| 410 | 44 (13.6) |
| 546 | 102 (31.5) |
| 819 | 176 (54.3) |
| Second dose | |
| Patients with ≥ 4 months of follow-up after first dose, n (%) | 275 (84.9) |
| Patients with a second dose, n (%) | 240 (87.3) |
| Days since last PP3M dose, mean ± SD [median] | 102.2 ± 46.3 [90.0] |
| Dose strength (mg), n (%) | |
| 273 | 1 (0.4) |
| 410 | 28 (11.7) |
| 546 | 82 (34.2) |
| 819 | 129 (53.8) |
| Third dose | |
| Patients with ≥ 4 months of follow-up after second dose, n (%) | 201 (62.0) |
| Patients with a third dose, n (%) | 169 (84.1) |
| Days since last PP3M dose, mean ± SD [median] | 90.6 ± 22.0 [85.0] |
| Dose strength (mg), n (%) | |
| 273 | 1 (0.6) |
| 410 | 18 (10.7) |
| 546 | 57 (33.7) |
| 819 | 93 (55.0) |
| Subsequent doses | |
| Patients with ≥ 4 months of follow-up after third dose, n (%) | 138 (42.6) |
| Patients with a subsequent dose, n (%) | 125 (90.6) |
| Days between subsequent dosesb, mean ± SD [median] | 94. 1 ± 31.7 [86.3] |
| Adherence to PP3M | |
| Patients with ≥ 2 PP3M claims, n (%) | 247 (76.2) |
| MPRc, mean ± SD [median] | 0.94 ± 0.14 [1.00] |
| MPRc ≥ 0.80, n (%) | 223 (90.3) |
| Patients with ≥ 12 months of observation period, n (%) | 151 (46.6) |
| PDC at 12 monthsd, mean ± SD [median] | 0.79 ± 0.24 [0.92] |
| PDC ≥ 0.80, n (%) | 91 (60.3) |
MPR medication possession ratio, PDC proportion of days covered, PP1M once-monthly paliperidone palmitate, PP3M once-every-3-months paliperidone palmitate, SD standard deviation
aContinuous PP3M therapy was defined as having a gap of no more than 45 days between the end of supply of a PP3M claim and the start of a new PP3M claim, starting from the index date
bAmong patients with more than three PP3M claims and at least 4 months of follow-up between claims
cMPR was calculated among patients with at least two claims of PP3M
dPDC was calculated as the sum of the number of unique days during which the patient had PP3M, divided by a fixed time interval